D-0120 is under clinical development by InventisBio and currently in Phase II for Gouty Arthritis (Gout). According to GlobalData, Phase II drugs for Gouty Arthritis (Gout) have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how D-0120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

D-0120 overview

D-0120 is under development for the treatment of hyperuricemia and gout. It is administered orally in the form of a tablet. It acts by targeting uric acid transporter 1 (URAT1).

InventisBio overview

InventisBio is a biotechnology company focused on discovery and development of novel therapeutics in the areas of oncology and metabolic diseases. The company is headquartered in Shanghai, China.

For a complete picture of D-0120’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.